Current Month 2006
Article Features
  Underserved African-American and White Women with Breast Cancer Have Similar Prognostic Profiles for Estrogen Receptor and Tumor Grade
Study Shows Drug Blocks Breast Cancer Migration to Bone
Developing a Breath Test to Detect Breast Cancer
COX-2 Inhibitors May Significantly Reduce Risk of Cancer
Study Finds Two Genes That May Predict Outcome for Breast Cancer Patients
Lack of Response to Herceptin May Be Reversed with Addition of a PI3K Inhibitor
Mammography Screenings for Breast Cancer Show Racial and Ethnic Disparities
Newer Chemotherapies Improve Outcomes for Some Types of Breast Cancer
The Relation of Overall and Central Obesity to Risk of Breast Cancer in African-American Women
Pregnant Women Should Not Ignore Breast Cancer Symptoms
Predicting the Recurrence of High-Risk Breast Cancers
Making Taxol More Effective and Available
Vitamin D Examined for Impact on Breast and Ovarian Cancers
Weight Training Benefits Mind and Body of Breast Cancer Survivors

Initial Results of the Study of Tamoxifen and Raloxifene (STAR) Released

The largest North American breast cancer prevention trial, the Study of Tamoxifen and Raloxifene, or STAR trial, has compiled an initial analysis of study data and found the osteoporosis drug raloxifene works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. Both drugs reduced the risk of developing invasive breast cancer by about 50 percent.

Tamoxifen (trade name Nolvadex®) ushered in the field of breast cancer chemoprevention. It has been used to treat women with breast cancer for more than 20 years, and based on findings from the landmark Breast Cancer Prevention Trial (BCPT), the drug was approved for use in 1998 to also help prevent breast cancer in women at high risk of developing the disease. But at about the same time, raloxifene (trade name Evista®), a drug approved to treat and prevent osteoporosis, also was found to reduce breast cancer incidence.

Both drugs - taken in pill form - manipulate a cell's use of the estrogen hormone, which can fuel the growth of tumors in breast tissue.

To test whether either of the drugs can offer superior protection against breast cancer, STAR was launched in 1999 by the non-profit research group, the National Surgical Breast and Bowel Project (NSABP), and was funded by the National Cancer Institute. In all, 19,747 women participated in the STAR clinical trial.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon